Fulgent Genetics Inc. reported its second quarter 2025 financial results, highlighting a 16% year-over-year increase in core revenue, reaching $81.7 million. The company has raised its full-year 2025 core revenue guidance to $320 million. Fulgent recorded a GAAP gross profit of $34.4 million, with a GAAP gross margin of 42.1%, while the non-GAAP gross profit stood at $36.2 million, or a non-GAAP gross margin of 44.2%. The company reported a GAAP loss of $19.0 million, or ($0.62) per share, which includes a one-time charge. On a non-GAAP basis, Fulgent posted an income of $2.1 million. Fulgent concluded the second quarter with $777.5 million in cash, cash equivalents, restricted cash, and investments in marketable securities. The company continues to focus on growing its Laboratory Services business and advancing clinical trials for its Therapeutic Development business.